Panel Discussion | Questions and Answers

Sunday, March 9, 2025

5:42 PM - 6:05 PM ET

Panel Moderator(s)

Nabil Dib, MD, MSc, FACC

Director Cardiovascular Research
Mercy Gilbert Medical Center/Dignity Health
Gilbert, Arizona, United States

No relationships to disclose
Stanton J. Rowe, PhD

CEO
NXT Biomedical
Irvine, California, United States

No relationships to disclose
Robert S. Schwartz, MD, FACC, FSCAI

President
DeHaan Center for Medical Innovation
Longboat Key, Florida, United States

Disclosure(s): Corflow: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Stock-privately held company (Ongoing)

Panel Discussant(s)

Takashi Akasaka, MD, PhD

Senior Consultant
Nishinomiya Watanabe Cardiovascular Cerebral Center
Nishinomiya, Hyogo, Japan

No relationships to disclose
Fabio S. Brito, Jr., MD

Director, Structural Heart Interventions
Instituto do Coracao (InCor)

Disclosure information not submitted.
Mehmet Cilingiroglu, MD

Professor
UT Houston MD Anderson Cancer Center
San Diego, California, United States

No relationships to disclose
William A. Gray, MD, FSCAI

System Chief of Cardiovascular Services, Main Line Health/President, Lankenau Heart Institute
Main Line Health
Wynnewood, Pennsylvania, United States

Disclosure information not submitted.
Gary Gershony, MD, FACC, FSCAI, FAHA, FRCPC

Interventional Cardiologist
John Muir Health Cardiovascular Institute
San Francisco, California, United States

No relationships to disclose
Chaim Shaul Lotan, MD

Chief Innovation Officer
Hadassah-Hebrew University Medical Center
Jerusalem, Israel

No relationships to disclose
Bill Shields, MBA

Vice President & General Manager
Medtronic
Mounds View, Minnesota, United States

Disclosure information not submitted.

Disclosure(s):

Nabil Dib, MD, MSc, FACC, FESC: Dib UltraNav Medical, LLC: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Stanton J. Rowe, PhD: Gradient Denervation: Director (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Nidus Biomedical: Employee (Ongoing), Salary (Ongoing), Stock-privately held company (Ongoing); Symbiosis Ltd: Consultant (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Vivifi Medical: Director (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Stock-privately held company (Ongoing)

Robert S. Schwartz, MD, FACC, FSCAI: Corflow: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Stock-privately held company (Ongoing)

Takashi Akasaka, MD, PhD: Daiichi Sankyo: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Nipro Co.: Consulting Fees (e.g., advisory boards) (Ongoing); Otsuka Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 5, 2024); Terumo Corporation: Employee (Ongoing)

Mehmet Cilingiroglu, MD: No financial relationships to disclose

William A. Gray, MD, FSCAI: Abbott Vascular, Medtronic, Boston Scientific: Grant/Research Support (Ongoing)

Gary Gershony, MD, FACC, FSCAI, FAHA, FRCPC: AtaCor Medical: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Chaim Shaul Lotan, MD: No financial relationships to disclose

Bill Shields, MBA: Medtronic: Employee (Ongoing)